Latest news with #BharatParenterals
Business Standard
30-07-2025
- Business
- Business Standard
Innoxel Lifesciences successfully completes USFDA inspection of its Vadodara unit
Bharat Parenterals announced that its subsidiary, Innoxel Lifesciences, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its finished dosage manufacturing facility in Vadodara, Gujarat. This follows the successful completion of the U.S. FDA inspection conducted from April 28 to May 2, 2025. The facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Liquid Injectables and Oral Liquids. With the receipt of the EIR, Innoxel Lifesciences has also received acceptance of the site for commercial operations for the product(s) under inspection. This milestone reinforces Innoxel's commitment to global quality benchmarks and enhances its capability to supply high-quality pharmaceutical products to regulated markets, such as United States and the European Union.
Business Standard
29-07-2025
- Business
- Business Standard
Bharat Parenterals consolidated net profit rises 542.97% in the June 2025 quarter
Sales rise 25.39% to Rs 116.00 crore Net profit of Bharat Parenterals rose 542.97% to Rs 8.23 crore in the quarter ended June 2025 as against Rs 1.28 crore during the previous quarter ended June 2024. Sales rose 25.39% to Rs 116.00 crore in the quarter ended June 2025 as against Rs 92.51 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 116.0092.51 25 OPM % 11.884.85 - PBDT 11.154.26 162 PBT 2.55-4.77 LP NP 8.231.28 543
Business Standard
12-05-2025
- Business
- Business Standard
Bharat Parenterals reports consolidated net loss of Rs 4.73 crore in the March 2025 quarter
Sales rise 53.32% to Rs 103.98 crore Net Loss of Bharat Parenterals reported to Rs 4.73 crore in the quarter ended March 2025 as against net loss of Rs 0.30 crore during the previous quarter ended March 2024. Sales rose 53.32% to Rs 103.98 crore in the quarter ended March 2025 as against Rs 67.82 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 12.63 crore in the year ended March 2025 as against net profit of Rs 14.51 crore during the previous year ended March 2024. Sales rose 30.30% to Rs 340.38 crore in the year ended March 2025 as against Rs 261.22 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 103.9867.82 53 340.38261.22 30 OPM % 2.141.47 - 0.7910.37 - PBDT 0.222.51 -91 1.3727.74 -95 PBT -8.30-1.36 -510 -33.9518.72 PL NP -4.73-0.30 -1477 -12.6314.51 PL
